Cerevel Therapeutics Holdings IncNASDAQ:CERE
- LAST PRICE41.8550
- TODAY'S CHANGE (%)0.3850 (0.9284%)
- Bid / Lots41.8500/ 3
- Ask / Lots41.8600/ 9
- Open / Previous Close41.6400 / 41.4700
- Day Range
- 52 Week Range
- Volume548,747
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CERE |
|---|---|---|
| 09:32 ET | 7683 | 41.5502 |
| 09:34 ET | 14846 | 41.515 |
| 09:36 ET | 1345 | 41.5 |
| 09:38 ET | 400 | 41.5 |
| 09:39 ET | 300 | 41.545 |
| 09:41 ET | 300 | 41.625 |
| 09:43 ET | 1500 | 41.65 |
| 09:45 ET | 286 | 41.66 |
| 09:48 ET | 1198 | 41.65 |
| 09:50 ET | 400 | 41.61 |
| 09:52 ET | 900 | 41.63 |
| 09:54 ET | 600 | 41.63 |
| 09:56 ET | 1987 | 41.585 |
| 09:57 ET | 615 | 41.605 |
| 09:59 ET | 550 | 41.6 |
| 10:01 ET | 1373 | 41.57 |
| 10:03 ET | 537 | 41.559 |
| 10:06 ET | 3313 | 41.55 |
| 10:08 ET | 900 | 41.535 |
| 10:10 ET | 3790 | 41.545 |
| 10:12 ET | 4975 | 41.555 |
| 10:14 ET | 638 | 41.54 |
| 10:15 ET | 204 | 41.53 |
| 10:17 ET | 600 | 41.535 |
| 10:19 ET | 700 | 41.55 |
| 10:21 ET | 809 | 41.54 |
| 10:24 ET | 492 | 41.545 |
| 10:26 ET | 324 | 41.55 |
| 10:28 ET | 600 | 41.545 |
| 10:30 ET | 1504 | 41.55 |
| 10:32 ET | 1200 | 41.555 |
| 10:35 ET | 500 | 41.555 |
| 10:37 ET | 1215 | 41.55 |
| 10:39 ET | 1000 | 41.59 |
| 10:42 ET | 1600 | 41.555 |
| 10:44 ET | 1252 | 41.56 |
| 10:46 ET | 700 | 41.57 |
| 10:48 ET | 1113 | 41.575 |
| 10:50 ET | 300 | 41.6 |
| 10:51 ET | 1700 | 41.56 |
| 10:53 ET | 1327 | 41.56 |
| 10:55 ET | 1000 | 41.545 |
| 10:57 ET | 700 | 41.545 |
| 11:00 ET | 200 | 41.55 |
| 11:02 ET | 900 | 41.545 |
| 11:04 ET | 500 | 41.56 |
| 11:06 ET | 831 | 41.578 |
| 11:08 ET | 600 | 41.58 |
| 11:09 ET | 8801 | 41.595 |
| 11:11 ET | 600 | 41.6 |
| 11:13 ET | 7972 | 41.6 |
| 11:15 ET | 6865 | 41.5925 |
| 11:18 ET | 8697 | 41.6 |
| 11:20 ET | 5347 | 41.585 |
| 11:22 ET | 500 | 41.6 |
| 11:24 ET | 500 | 41.61 |
| 11:26 ET | 1120 | 41.5938 |
| 11:27 ET | 200 | 41.595 |
| 11:29 ET | 1000 | 41.62 |
| 11:31 ET | 1753 | 41.615 |
| 11:33 ET | 1200 | 41.605 |
| 11:36 ET | 2023 | 41.61 |
| 11:38 ET | 1000 | 41.62 |
| 11:40 ET | 1200 | 41.635 |
| 11:42 ET | 600 | 41.64 |
| 11:44 ET | 1178 | 41.63 |
| 11:45 ET | 300 | 41.63 |
| 11:47 ET | 500 | 41.63 |
| 11:49 ET | 300 | 41.615 |
| 11:51 ET | 700 | 41.62 |
| 11:54 ET | 1100 | 41.645 |
| 11:56 ET | 7104 | 41.65 |
| 11:58 ET | 767 | 41.66 |
| 12:00 ET | 800 | 41.67 |
| 12:02 ET | 600 | 41.69 |
| 12:03 ET | 800 | 41.7 |
| 12:05 ET | 700 | 41.7 |
| 12:07 ET | 5078 | 41.69 |
| 12:09 ET | 1245 | 41.7 |
| 12:12 ET | 600 | 41.7 |
| 12:14 ET | 1734 | 41.685 |
| 12:16 ET | 1100 | 41.675 |
| 12:18 ET | 1184 | 41.65 |
| 12:20 ET | 400 | 41.67 |
| 12:21 ET | 793 | 41.69 |
| 12:23 ET | 1090 | 41.7 |
| 12:25 ET | 3600 | 41.69 |
| 12:27 ET | 3104 | 41.7 |
| 12:30 ET | 800 | 41.67 |
| 12:32 ET | 300 | 41.67 |
| 12:34 ET | 500 | 41.67 |
| 12:36 ET | 1230 | 41.685 |
| 12:38 ET | 2600 | 41.675 |
| 12:39 ET | 2297 | 41.64 |
| 12:41 ET | 552 | 41.65 |
| 12:43 ET | 3533 | 41.695 |
| 12:45 ET | 6890 | 41.69 |
| 12:48 ET | 400 | 41.68 |
| 12:50 ET | 1600 | 41.685 |
| 12:52 ET | 800 | 41.7 |
| 12:54 ET | 800 | 41.7 |
| 12:56 ET | 500 | 41.7 |
| 12:57 ET | 400 | 41.7 |
| 12:59 ET | 900 | 41.7 |
| 01:01 ET | 1000 | 41.7 |
| 01:03 ET | 25265 | 41.745 |
| 01:06 ET | 27302 | 41.75 |
| 01:08 ET | 3000 | 41.72 |
| 01:10 ET | 6512 | 41.73 |
| 01:12 ET | 1100 | 41.735 |
| 01:14 ET | 406 | 41.725 |
| 01:15 ET | 3622 | 41.795 |
| 01:17 ET | 300 | 41.785 |
| 01:19 ET | 1500 | 41.785 |
| 01:21 ET | 373 | 41.78 |
| 01:24 ET | 300 | 41.79 |
| 01:26 ET | 410 | 41.775 |
| 01:28 ET | 1327 | 41.79 |
| 01:30 ET | 444 | 41.79 |
| 01:32 ET | 67618 | 41.78 |
| 01:33 ET | 15031 | 41.805 |
| 01:35 ET | 3556 | 41.79 |
| 01:37 ET | 7749 | 41.81 |
| 01:39 ET | 200 | 41.805 |
| 01:42 ET | 400 | 41.825 |
| 01:44 ET | 1030 | 41.785 |
| 01:46 ET | 400 | 41.805 |
| 01:48 ET | 700 | 41.8 |
| 01:50 ET | 300 | 41.8 |
| 01:51 ET | 1200 | 41.8 |
| 01:53 ET | 200 | 41.805 |
| 01:55 ET | 300 | 41.815 |
| 01:57 ET | 300 | 41.815 |
| 02:00 ET | 3528 | 41.83 |
| 02:02 ET | 450 | 41.84 |
| 02:04 ET | 17107 | 41.805 |
| 02:06 ET | 1000 | 41.81 |
| 02:08 ET | 600 | 41.82 |
| 02:09 ET | 450 | 41.82 |
| 02:11 ET | 703 | 41.84 |
| 02:13 ET | 798 | 41.845 |
| 02:15 ET | 700 | 41.85 |
| 02:18 ET | 1704 | 41.825 |
| 02:20 ET | 650 | 41.83 |
| 02:22 ET | 300 | 41.84 |
| 02:24 ET | 600 | 41.84 |
| 02:26 ET | 700 | 41.84 |
| 02:27 ET | 500 | 41.85 |
| 02:29 ET | 400 | 41.855 |
| 02:31 ET | 6227 | 41.88 |
| 02:33 ET | 700 | 41.89 |
| 02:36 ET | 1519 | 41.885 |
| 02:38 ET | 500 | 41.89 |
| 02:40 ET | 1000 | 41.875 |
| 02:42 ET | 900 | 41.875 |
| 02:44 ET | 1098 | 41.87 |
| 02:45 ET | 300 | 41.865 |
| 02:47 ET | 2500 | 41.865 |
| 02:49 ET | 2000 | 41.87 |
| 02:51 ET | 8248 | 41.87 |
| 02:54 ET | 1514 | 41.8599 |
| 02:56 ET | 1900 | 41.86 |
| 02:58 ET | 6794 | 41.88 |
| 03:00 ET | 2300 | 41.865 |
| 03:02 ET | 1600 | 41.845 |
| 03:03 ET | 14286 | 41.875 |
| 03:05 ET | 904 | 41.855 |
| 03:07 ET | 1625 | 41.86 |
| 03:09 ET | 1606 | 41.845 |
| 03:12 ET | 400 | 41.85 |
| 03:14 ET | 400 | 41.86 |
| 03:16 ET | 3908 | 41.85 |
| 03:18 ET | 100 | 41.86 |
| 03:20 ET | 900 | 41.86 |
| 03:21 ET | 1993 | 41.855 |
| 03:23 ET | 900 | 41.86 |
| 03:25 ET | 2515 | 41.86 |
| 03:27 ET | 3165 | 41.86 |
| 03:30 ET | 1800 | 41.855 |
Today
CEREVEL STOCK INQUIRY: Is $45 Per Share Enough for Cerevel (CERE)? Contact BFA Law about Ongoing Investigation into the Deal Price, from 2 minutes ago by Dow Jones
2 minutes ago by Dow JonesCERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesCEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoing Investigation into the Deal Price, from 9 hours ago by Dow Jones
9 hours ago by Dow Jones
Yesterday
CEREVEL INVESTOR UPDATE: BFA Law is Investigating Whether $45 Per Share is Too Low for Cerevel (CERE), and Reminds Shareholders to Contact the Firm, from 3:43PM ET on Monday Jun 17, 2024 by Dow Jones
3:43PM ET on Monday Jun 17, 2024 by Dow JonesCEREVEL NOTIFICATION: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoing Investigation into the Acquisition Price, from 6:33AM ET on Monday Jun 17, 2024 by Dow Jones
6:33AM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cerevel Therapeutics Holdings Inc | 7.6B | -15.4x | --- |
Vaxcyte Inc | 7.8B | -17.0x | --- |
Cytokinetics Inc | 6.1B | -9.6x | --- |
Revolution Medicines Inc | 6.1B | -10.0x | --- |
Madrigal Pharmaceuticals Inc | 5.9B | -12.0x | --- |
Viking Therapeutics Inc | 5.7B | -54.8x | --- |
Company Information
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Contact Information
- Headquarters
- 222 Jacobs Street, Suite 200CAMBRIDGE, MA, United States 02141
- Phone
- 212-284-2300
- Fax
- 302-636-5454
Executives
- Chairperson of the Board of Directors
- N. Anthony Coles
- President, Chief Executive Officer, Member of the Board
- Ronald Renaud
- Chief Financial Officer
- Susan Altschuller
- Chief Human Resources Officer
- Kenneth Dipietro
- Senior Vice President - Finance, Chief Accounting Officer
- Mark Bodenrader
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.6B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 182.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.41 |
EPS | $-2.72 |
Book Value | $3.71 |
P/E Ratio | -15.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
